Study details
Enrolling now
EVO101 Topical Cream for Hidradenitis Suppurativa
Virginia Clinical Research, Inc.
NCT IDNCT06645821ClinicalTrials.gov data as of Apr 2026
Phase
EARLY_PHASE1
Target enrollment
15
Study length
about 6 months
Ages
18+
Locations
1 site in VA
What this study is about
This trial is testing EVO101, a topical cream, to treat mild to moderate hidradenitis suppurativa in adults. Participants will apply the cream and visit clinics to track their symptoms and disease progression.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take EVO101
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Endpoints
Primary: The efficacy of EVO101 on hidradenitis suppurativa will be evaluated using two parameters: decrease in lesion count and change in patient reported outcomes (PRO)